Tisotumab vedotin

G. D'Alessandro, Fabio Barra, A. Boutros, G. Evangelisti, L. Ferro Desideri, M. Moioli, S. Ferrero

Research output: Contribution to journalArticlepeer-review

Abstract

Tisotumab vedotin (TV) is a humanized antibody-drug conjugate (ADC) directed against tissue factor, a protein involved in signaling pathways related to angiogenesis, cell adhesion, motility and survival. It has been reported that tissue factor is aberrantly expressed by many types of solid tumors and it is associated with negative oncological outcomes. ADCs combine monoclonal antibodies directed to surface antigens of specific tumor cells with highly potent anticancer agents linked via a chemical linker. After promising activity in vitro and in animal models, a multicenter, open-label phase I-II clinical trial (InnovaTV 201) reported an overall response rate of 15.6% and a median progression-free survival of 3 months in patients with solid advanced cancers who underwent TV therapy. In particular, a subanalysis demonstrated that TV had efficacy against cervical cancer with a good tolerability profile. Phase II clinical studies are ongoing to further investigate the efficacy and safety of TV as monotherapy or in combination with other targeted or cytotoxic drugs in patients with advanced cancer.

Original languageEnglish
Pages (from-to)717-724
Number of pages8
JournalDrugs of the Future
Volume45
Issue number10
DOIs
Publication statusPublished - Oct 2020

Keywords

  • Advanced cancer
  • Angiogenesis
  • Antibody-drug conjugate
  • HuMab-TF-011-vcMMAE
  • HuMax-TF-ADC
  • TF-011-MMAE
  • Tisotumab vedotin
  • Tissue factor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tisotumab vedotin'. Together they form a unique fingerprint.

Cite this